|
[1]
|
Shah M, Dorman SE. Latent tuberculosis infection. N Engl J Med 2021;385(24):2271 − 80. https://doi.org/10.1056/NEJMcp2108501CrossRef
|
|
[2]
|
WHO. Guidelines on the management of latent tuberculosis infection. 2015. https://www.who.int/publications/i/item/9789241548908. [2015-1-1]. |
|
[3]
|
Huang W, Fang ZX, Luo S, Lin S, Xu L, Yan B, et al. The effect of BCG vaccination and risk factors for latent tuberculosis infection among college freshmen in China. Int J Infect Dis 2022;122:321 − 6. https://doi.org/10.1016/j.ijid.2022.06.010CrossRef
|
|
[4]
|
Su Q, Wang QY, Zhang T, Liu Y. Comparison of recombinant Mycobacterium tuberculosis fusion protein skin test and tuberculin skin test for screening latent tuberculosis infection in school students. Chin J Infect Control 2023;22(5):547 − 51. https://doi.org/10.12138/j.issn.1671-9638.20233724CrossRef
|
|
[5]
|
WHO. Rapid communication: TB antigen-based skin tests for the diagnosis of TB infection. 2022. https://www.who.int/publications/i/item/WHO-UCN-TB-2022.1. [2022-4-4]. |
|
[6]
|
Krutikov M, Faust L, Nikolayevskyy V, Hamada Y, Gupta RK, Cirillo D, et al. The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis. Lancet Infect Dis 2022;22(2):250 − 64. https://doi.org/10.1016/S1473-3099(21)00261-9CrossRef
|
|
[7]
|
Xu M, Lu W, Li T, Li JX, Du WX, Wu Q, et al. Sensitivity, specificity, and safety of a novel ESAT6-CFP10 skin test for tuberculosis infection in China: 2 randomized, self-controlled, parallel-group phase 2b trials. Clin Infect Dis 2022;74(4):668 − 77. https://doi.org/10.1093/cid/ciab472CrossRef
|
|
[8]
|
Yang Z, Sun Q, Han L, Bao C, Wang X, Zhang ZG. Analysis of recombinant mycobacterium tuberculosis fusion protein in screening for latent tuberculosis infection in college students. Chin J Front Med Sci (Electron Vers) 2022;14(7):51 − 4. https://doi.org/10.12037/YXQY.2022.07-10CrossRef
|
|
[9]
|
Wang WJ, Liu Q, Miao CD, Chen JJ, Wang Z, Zhu LM, et al. Status and influencing factors of latent tuberculosis infection among middle school students in Taizhou from 2019 to 2021. Chin J Dis Control Prev 2022;26(11):1264 − 70. https://doi.org/10.16462/j.cnki.zhjbkz.2022.11.005CrossRef
|
|
[10]
|
Gao L, Lu W, Bai LQ, Wang XH, Xu JS, Catanzaro A, et al. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis 2015;15(3):310 − 9. https://doi.org/10.1016/S1473-3099(14)71085-0CrossRef
|
|
[11]
|
Ruhwald M, Aggerbeck H, Gallardo RV, Hoff ST, Villate JI, Borregaard B, et al. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial. Lancet Respir Med 2017;5(4):259 − 68. https://doi.org/10.1016/S2213-2600(16)30436-2CrossRef
|
|
[12]
|
Hauck FR, Neese BH, Panchal AS, El-Amin W. Identification and management of latent tuberculosis infection. Am Fam Physician 2009;79(10):879-86. https://www.aafp.org/pubs/afp/issues/2009/0515/p879.html. |
|
[13]
|
Muñoz L, Stagg HR, Abubakar I. Diagnosis and management of latent tuberculosis infection. Cold Spring Harb Perspect Med 2015;5(11):a017830. https://doi.org/10.1101/cshperspect.a017830CrossRef
|
|
[14]
|
Nikitina IY, Karpina NL, Kasimceva OV, Gergert VY, Ergeshov A, Lyadova IV. Comparative performance of QuantiFERON-TB Gold versus skin test with tuberculosis recombinant allergen (Diaskintest) among patients with suspected pulmonary tuberculosis in Russia. Int J Infect Dis 2019;86:18 − 24. https://doi.org/10.1016/j.ijid.2019.06.014CrossRef
|
|
[15]
|
Kunst H. Diagnosis of latent tuberculosis infection: the potential role of new technologies. Respir Med 2006;100(12):2098 − 106. https://doi.org/10.1016/j.rmed.2006.02.032CrossRef
|